University Hospitals Birmingham NHS Foundation Trust

Reports

Status Drug name NICE TAs Comments
Status: Amber Aveeno cream

Amber - oncology use

Green - paediatrics only

Status: Amber Aviptadil 25mcg / Phentolamine 2mg intracavernosal injection (Invicorp®)

Approved on formulary December 2017. Specialist initiation. Third line after oral PDE-5 inhibitors failed and patient not responding to or intolerant of alprostadil. To be reviewed within 12 months to assess alprostadil supply issues and patent expiry

Status: Amber Aymes® creme (semi-solid)
Status: Amber Azarga eye drops

Specialist ophthalmologist recommendation

Status: Amber Azathioprine

To be administered in conjunction with prednisolone (plain tablets). Supported by ESCA.

Status: Amber Azathioprine tablets

ESCA

Status: Amber Azathioprine

Supported by ESCA

Status: Amber Azathioprine

Azathioprine Dermatology ESCA

Status: Amber Azithromycin dihydrate drops

First line for ophthalmic chylamydia

Status: Amber Azithromycin tablets

RICaD

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.

Building healthier lives
Back to top